CGTX
Cognition Therapeutics, Inc.1.5200
-0.0800-5%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
134.18MP/E (TTM)
-Basic EPS (TTM)
-0.47Dividend Yield
0%Recent Filings
8-K
8-K
Q3 loss narrows; FDA path cleared
Cognition Therapeutics reported a Q3 2025 net loss of $4.9 million, down from $9.9 million last year, thanks to slashed R&D spending after wrapping up key trials. Cash hit $39.8 million post a $30 million stock offering, funding ops into Q2 2027 while advancing zervimesine toward Alzheimer's registration following FDA alignment. Enrollment topped 75% in the Phase 2 START study. Yet risks linger in trial outcomes.
10-Q
Q3 FY2025 results
Cognition Therapeutics narrowed its Q3 net loss to $4.9M from $9.9M a year earlier, thanks to lower R&D spending that dropped 67% y/y to $3.8M amid wrapping up Phase 2 trials, while grant income fell to $1.2M from $4.3M. For the first nine months, the net loss improved 23% y/y to $20.1M, with operating expenses down 21% to $34.1M, reflecting tighter cost controls on clinical programs. Cash swelled to $39.3M by quarter-end, boosted by a $27.9M registered direct offering closed in August 2025 for 14.7M shares at $2.05 each, plus $8.3M from ATM sales; free cash flow isn't disclosed in the 10-Q. The August offering included placement agent warrants for 514,500 shares at $2.78, exercisable after six months for five years. Yet funding remains a tightrope, with ongoing trials demanding more capital.
8-K
Zervimesine Phase 2 highlights
Cognition Therapeutics released an investor presentation on September 15, 2025, highlighting Phase 2 data for zervimesine, an oral oligomer antagonist showing consistent efficacy signals in Alzheimer's, dementia with Lewy bodies, and dry AMD. Key results include 95% slowing of cognitive decline in low p-tau217 Alzheimer's patients, up to 91% slowing across DLB symptom domains, and 29% reduction in GA lesion growth rate versus placebo. The drug's favorable safety profile supports advancing to Phase 3 trials, backed by $11.6M cash and $42M remaining grants. Zervimesine advances swiftly.
8-K
Cognition Therapeutics raises $30M
Cognition Therapeutics entered a registered direct offering on August 27, 2025, selling 14.7 million common shares to two institutional investors at $2.05 per share, netting about $30.1 million in gross proceeds before fees. The deal, closing August 29 via shelf registration, bolsters the biotech's cash for working capital amid clinical pushes. Yet dilution looms large for shareholders. Funds fuel operations.
ACOG
Alpha Cognition Inc.
5.43+0.42
CING
Cingulate Inc.
3.87-0.28
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
COYA
Coya Therapeutics, Inc.
5.83-0.08
DSGN
Design Therapeutics, Inc.
9.62+0.50
GANX
Gain Therapeutics, Inc.
3.86-0.09
IGC
IGC Pharma, Inc.
0.34+0.00
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
SAVA
Cassava Sciences, Inc.
2.93+0.13
VYGR
Voyager Therapeutics, Inc.
4.42+0.06